The purpose of this study is to develop a dedicated MRI scan of the pancreas (MRP) to better detect pancreatic cancer in people who are at a high risk for pancreatic cancer.

Inclusion Criteria:

• Two first-degree relatives with pancreas cancer, one being a first-degree relative to the individual
• Pathogenic mutation in APC, BRCA1, MLH1, MSH2, MSH6, PMS2, EPCAM, PALB2, or TP53 and a first/second-degree relative with pancreas cancer
• Pathogenic mutation in CDKN2A/p16, STK11, PRSS1, SPINK1/PST1, CTRC, CPA1, ATM, or BRCA2
• Meets surveillance age eligibility, which is typically age 50, or 10 years earlier than the youngest relative with pancreas cancer. For individuals with certain gene mutations, this can be earlier. All participants must be aged 21+

For this pilot MRP study, we will additionally apply the following Criteria:

• Consents to follow-up contact
• US residents
• Completed MRI with MRCP with no actionable findings related to the pancreas (e.g. a pancreatic mass)
• No metallic artifacts covering the pancreas on prior MRCP
• Scheduled for endoscopic ultrasound
• No new contraindications for MRI (e.g. new MR unsafe device)
• No history of claustrophobia or use of anxiolytic on prior MRI
• No history of abdominal surgery that may affect interpretation of either EUS or MR
• No medical conditions that confers increased and/or unacceptable risk for anesthesia

We will recruit surveillance participants who had at least one prior MRCP in the last 3 years. They must also undergo a same-day EUS procedure as part of their surveillance. Nearly all active cohort participants have had at least one recent MRCP and, on average, our Registry gastroenterologist Dr. Rolston performs EUS in ~260 surveillance participants per year. Accordingly, it is highly feasible to recruit more than 79 participants in the grant period, and recruitment is constrained by budget.

• Documentation of Disease

  o No pathologic confirmation of disease is necessary

• Definition of Disease N/A

• Required Organ Function N/A

Exclusion Criteria:

-

Investigators will conduct this pilot study in high-risk individuals enrolled in the Memorial Sloan Kettering Pancreatic Tumor Registry

• Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.